Pembrolizumab

ClinicalJuly 18, 2026

Merck's Pembrolizumab Study Targets Japanese Pediatric and Adult Cancer Patients

Merck is conducting a study to evaluate the safety and efficacy of pembrolizumab in Japanese pediatric participants with solid tumors and lymphomas, as well as in adults with Merkel cell carcinoma.

Sponsor company

Mechanism of action

Recent signals(26)

Study of Pembrolizumab Plus MK-1084 in NSCLC with KRAS G12C Mutations

Phase 1/2 Study of Investigational Agents with Pembrolizumab in Advanced Esophageal Cancer

Phase 1 Trial of M3T01 Monotherapy and Combination Therapy in Solid Tumors

Pembrolizumab Trial for Small Cell Carcinoma of Ovary - Hypercalcemic Type

Pembrolizumab and Lenvatinib Trial for Unresectable Cutaneous Angiosarcoma Initiated

Phase I Trial of Pembrolizumab for Neurological Symptoms Post-COVID-19

BRIGHT Trial: Pembrolizumab and Radiation Therapy for Muscle Invasive Bladder Cancer

Merck's Pembrolizumab Study Targets Japanese Pediatric and Adult Cancer Patients

Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab

FDA Approves Pembrolizumab Combinations for Muscle Invasive Bladder Cancer

Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival

Merck and Daiichi Sankyo Launch ESCC Combination Therapy Study with Pembrolizumab

Novel tumor inflammation score predicts outcomes in NSCLC patients treated with pembrolizumab and gemcitabine

Phase 2 Trial of Pembrolizumab for Poor-Prognosis CUP Patients Initiated

Merck's Sacituzumab Tirumotecan and Pembrolizumab Combo Trial in NSCLC Underway

E-VIRTUE Trial to Evaluate Enfortumab Vedotin with Pembrolizumab in Rare Genitourinary Tumors

Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial

FDA approves sacituzumab govitecan-hziy for first-line triple-negative breast cancer

Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer

Merck's KEYMAKER-U01 Study Explores Pembrolizumab in NSCLC with Chemotherapy

Phase II Trial of Axelopran with Pembrolizumab in Head and Neck Cancer

FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment

Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy

Phase III Trial Evaluates Pembrolizumab Timing in NSCLC Treatment

Phase III Trial of Pembrolizumab Plus Doxorubicin in Aggressive Sarcomas

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

Upcoming milestones

Related catalysts(1)

Merck — Pembrolizumab

Indications

Therapeutic areas

Get signals before the market moves